Literature DB >> 24035689

Challenging the clinical relevance of folinic acid over rescue after high dose methotrexate (HDMTX).

Ian J Cohen1.   

Abstract

THE HYPOTHESIS: The use of adequate folinic acid rescue (in clinically relevant doses) after high dose methotrexate will prevent neurotoxicity without reducing treatment results.
METHODS: A literature search was performed to test the hypothesis that no evidence for the existence of folinic acid over-rescue of high-dose methotrexate (MTX) in clinically relevant situations exists (evidence that too much folinic acid reduced cure rate). EMPIRICAL DATA: Examples of folinic acid over-rescue after lower doses of MTX were found and has been cited as evidence of over rescue of high dose MTX. Mega doses of folinic acid, used when toxic levels of MTX occurred, also could neutralize the MTX effect. Data were found to support the contention that higher levels of MTX require disproportionally higher folinic acid doses for rescue. Careful examination of the available studies after HDMTX yielded more convincing alternative explanations for reduction in cure rate than over rescue. Little convincing evidence for the existence of over rescue after HDMTX was found. DISCUSSION: The rescue of high-dose MTX with an appropriate dose of folinic acid that can prevent toxicity, especially neurotoxicity, was not shown to reduce the therapeutic effect. No evidence was found that higher doses of folinic acid after high dose MTX reduces the therapeutic effect. CONSEQUENCES OF THE HYPOTHESIS: Acceptance of the hypothesis can prevent harm being caused (especially brain damage) by reversing the trend of dose reduction in FA rescue. The recognition that the use of higher folinic acid doses is safe, can prevent neurotoxicity, and does not reduce prognosis has important implications for the development of effective non toxic treatment protocols.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24035689     DOI: 10.1016/j.mehy.2013.08.027

Source DB:  PubMed          Journal:  Med Hypotheses        ISSN: 0306-9877            Impact factor:   1.538


  8 in total

1.  Reply to: methotrexate administration directly into the fourth ventricle in children with malignant fourth ventricular brain tumors: a pilot clinical trial.

Authors:  Ian J Cohen
Journal:  J Neurooncol       Date:  2016-01-05       Impact factor: 4.130

2.  The importance of adequate methotrexate and adequate folinic acid rescue doses in the treatment of primary brain lymphoma.

Authors:  Ian J Cohen
Journal:  J Neurooncol       Date:  2018-09-21       Impact factor: 4.130

3.  Early, empiric high-dose leucovorin rescue in lymphoma patients treated with sequential doses of high-dose methotrexate.

Authors:  Jason N Barreto; Kristen T Peterson; Erin F Barreto; Kristin C Mara; Ross A Dierkhising; Nelson Leung; Thomas E Witzig; Carrie A Thompson
Journal:  Support Care Cancer       Date:  2021-03-04       Impact factor: 3.603

Review 4.  Non-infectious chemotherapy-associated acute toxicities during childhood acute lymphoblastic leukemia therapy.

Authors:  Kjeld Schmiegelow; Klaus Müller; Signe Sloth Mogensen; Pernille Rudebeck Mogensen; Benjamin Ole Wolthers; Ulrik Kristoffer Stoltze; Ruta Tuckuviene; Thomas Frandsen
Journal:  F1000Res       Date:  2017-04-07

5.  More severe toxicity of genetic polymorphisms on MTHFR activity in osteosarcoma patients treated with high-dose methotrexate.

Authors:  Lu Xie; Wei Guo; Yi Yang; Tao Ji; Jie Xu
Journal:  Oncotarget       Date:  2017-12-14

6.  The evaluation of red blood cell folate and methotrexate levels during protocol M in childhood acute lymphoblastic leukemia.

Authors:  N Oosterom; M Fiocco; R Q H Kloos; I M van der Sluis; R Pieters; B D van Zelst; D E C Smith; M M van den Heuvel-Eibrink; R de Jonge; S G Heil
Journal:  BMC Cancer       Date:  2020-09-30       Impact factor: 4.430

7.  Reduced dose folinic acid rescue after rapid high-dose methotrexate clearance is not associated with increased toxicity in a pediatric cohort.

Authors:  Riitta Niinimäki; Henri Aarnivala; Joanna Banerjee; Tytti Pokka; Kaisa Vepsäläinen; Arja Harila-Saari
Journal:  Support Care Cancer       Date:  2021-07-08       Impact factor: 3.603

8.  Monitoring Of High-Dose Methotrexate (Mtx)-Related Toxicity and Mtx Levels in Children with Acute Lymphoblastic Leukemia: A Pilot-Study in Indonesia.

Authors:  Nur Melani Sari; Lulu E Rakhmilla; Muhammad Hasan Bashari; Zulfan Zazuli; Nur Suryawan; Susi Susanah; Lelani Reniarti; Harry Raspati; Eddy Supriyadi; Gertjan J L Kaspers; Ponpon Idjradinata
Journal:  Asian Pac J Cancer Prev       Date:  2021-07-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.